A recent study published in the Journal of Affective Disorders suggests that a single dose of psilocybin may offer hope for U ...

Intra-Cellular Therapies’ atypical antipsychotic medication Caplyta has been on a roll, delivering fast commercial growth and coming up triumphant in yet another late-stage trial. | Intra-Cellular ...

When 73-year-old Ravi went to a primary health centre at Bardez, Goa, to address his exhaustion and sleep problems, little did the healthcare worker realise that these were tell-tale signs of ...

Patients with non-seasonal depression who were treated with bright light therapy reported a 40% remission rate, according to a recent study.

The field of digital therapeutics for mood disorders has witnessed rapid advancements, harnessing cutting-edge technologies to provide personalized, accessible support. These interventions leverage AI ...

Three years after $20 million in federal pandemic aid allowed the University of Iowa in 2021 to open a new “Center for School ...

Approved in March 2019, esketamine is currently indicated for use alongside an oral antidepressant for treatment-resistant ...

Unsupervised use of hallucinogens like LSD is high, posing significant risks. However, LSD is being clinically tested for treating anxiety and so far seems effective.

The mental health of young people has never been more important. At Independence Blue Cross (IBX), we are strengthening our ...

Patients with comorbid depression and insomnia do not feel satisfied by their health care providers or available treatment options.

Analyst Vikram Purohit of Morgan Stanley maintained a Buy rating on COMPASS Pathways (CMPS – Research Report), with a price target of ...

Compared with usual care, care via the PROVIDE model, a mode of telemedicine, may improve the mental health of patients with depression and anxiety disorders.